Off-label use of ultrasound contrast agents for abdominal imaging in the United States

Journal of Ultrasound in Medicine

Volumn 32, Issue 1, 2013, Pages 7-12

  Barr, Richard G ^a,b  

^a Northeastern Ohio Medical University   (United States)

^b Radiology Consultants Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMINOID; CONTRAST MEDIUM; DIAGNOSTIC AGENT; FLUOROCARBON; PERFLUTREN;

ABDOMEN; ARTICLE; COMPUTER PROGRAM; ECHOGRAPHY; FOOD AND DRUG ADMINISTRATION; HUMAN; OFF LABEL DRUG USE; UNITED STATES;

ABDOMEN; ALBUMINS; CONTRAST MEDIA; FLUOROCARBONS; HUMANS; OFF-LABEL USE; SOFTWARE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84871758315     PISSN: 02784297     EISSN: 15509613     Source Type: Journal    
DOI: 10.7863/jum.2013.32.1.7     Document Type: Note

References (23)

1. Claudon M, Cosgrove D, Albrecht T, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS): update 2008. Ultraschall Med 2008; 29:28-44 (Pubitemid 351294171)
2. Piscaglia F, Nolsøe C, Dietrich CF, et al. The EFSUMB guidelines and recommendations on the clinical practice of contrast enhanced ultrasound (CEUS): update 2011 on non-hepatic applications. Ultraschall Med 2012; 33:33-59
3. US Food and Drug Administration. "Off-label" and investigational use of marketed drugs, biologics, and medical devices: information sheet. US Food and Drug Administration website. http://www.fda.gov/ RegulatoryInformation/Guidances/ucm126486.htm. Updated August 10, 2011
4. Wilson SR, Kim TK, Jang HJ, Burns PN. Enhancement patterns of focal liver masses: discordance between contrast-enhanced sonography and contrast- enhanced CT and MRI. AJR Am J Roentgenol 2007; 189:W7-W12
5. Robbin ML, Lockhart ME, Barr RG. Renal imaging with ultrasound contrast: current status. Radiol Clin North Am 2003; 41:963-978 (Pubitemid 37152086)
6. Quala E. Microbubble ultrasound contrast agents: an update. Eur Radiol 2007; 17:1995-2008
7. Cosgrove D. Ultrasound contrast agents: an overview. Eur J Radiol 2006; 60:324-330
8. Solbiati L, Martegani A, Leen E, Correas JM. Contrast-Enhanced Ultrasound of Liver Diseases. New York, NY: Springer; 2003
9. Wilson SR, Burns PN. Microbubble-enhanced US in body imaging: what role? Radiology 2010; 257:24-39
10. Iezzi R. Cotroneo AR, Basilico A, Simeone A, Storto ML, Bonomo L. Endoleaks after endovascular repair of abdominal aortic aneurysm: value of CEUS. Abdom Imaging 2010; 35:106-114
11. Ripollés T, Martinez-Pérez MJ, Blanc E, et al. Contrast-enhanced ultrasound (CEUS) in Crohn's disease: technique, image interpretation, and clinical applications. Insights Imaging 2011; 2:639-652
12. Main ML, Ryan AC, Davis TE, Albano MP, Kusnetzky LL, Hibberd M. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (multicenter registry results in 4,300,966 consecutive patients). Am J Cardiol 2008; 102:1742-1746. 13.
13. Exuzides A, Main ML, Colby C, Grayburn PA, Feinstein SB, Goldman JH. A retrospective comparison of mortality in critically ill hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent. JACC Cardiovasc Imaging 2010; 3:578-585
14. Abdelmoneim SS, Bernier M, Scott CG, et al. Safety of contrast agent use during stress echocardiography: a 4-year experience from a single-center cohort study of 26,774 patients. JACC Cardiovasc Imaging 2009; 2:1048- 1056
15. Main ML. Ultrasound contrast agent safety: from anecdote to evidence. JACC Cardiovasc Imaging 2009; 2:1057-1059
16. Barr RG. Evaluation of indeterminate renal masses with contrastenhanced ultrasound [abstract]. J Ultrasound Med 2012; 31(suppl):S24
17. Sanchez K, Barr RG. Contrast-enhanced ultrasound detection and treatment guidance in a renal transplant patient with renal cell carcinoma. Ultrasound Q 2009: 25;171-173
18. US Food and Drug Administration. Guidance for industry: harmonic imaging with/without contrast - premarket notification requirements. US Food and Drug Administration website. http://www.fda.gov/MedicalDevices/ DeviceRegulationandGuidance/GuidanceDocuments/ucm073807.htm. Updated June 18, 2009
19. Lantheus Medical Imaging. Definity: prescribing information. Lantheus Medical Imaging website; 2012. http://www.definityimaging.com/prescribing-info. html
20. GE Healthcare. Optison. GE Healthcare website. http://optisonimaging.com/ files/optison-pi.pdf. Revised August 2012
21. Calliada F, Campani R, Bottinelli O, Bozzini A, Sommaruga MG. Ultrasound contrast agents: basic principles. Eur J Radiol 1998; 27(suppl 2):S157-S160 (Pubitemid 28270589)
22. Goldberg BB, Raichlen JS, Forsberg F. Ultrasound Contrast Agents: Basic Principles and Clinical Applications. London, England: Taylor & Francis Group; 2001
23. ICD9Data.com. 2012 HCPCS code Q9957: injection, perflutren lipid microspheres, per ml. ICD9Data.com website; 2012. http://www.icd9data.com/HCPCS/ 2012/Q/Q9957.htm